Absorption Mechanism of 1,3-Bis(2-ethoxycarbonylchromon-5-yloxy)-2-((S)-lysyloxy)propane Dihydrochloride (N-556), a Prodrug for the Oral Delivery of Disodium Cromoglycate
スポンサーリンク
概要
- 論文の詳細を見る
To clarify the absorption mechanism of 1,3-bis(2-ethoxycarbonylchromon-5-yloxy)-2-((S)-lysyloxy)propane dihydrochloride (N-556), a prodrug for the oral delivery of disodium cromoglycate (DSCG), a study was made using rats. N-556 gave the highest plasma level of DSCG following its injection into the loop at the upper part of the small intestine. N-556 was stable in acidic washings of gastric contents, but rapidly hydrolyzed to M1 with twin ethyl residues on DSCG in the washings of the small intestinal contents. N-556 and M1 were hydrolyzed to DSCG via M2 having a mono ethyl residue in the homogenate of the small intestinal mucosa. The oral absorption of M1 following its administration in 50% (v/v) propylene glycol solution was essentially the same as that of N-556. That of M1 administered in aqueous suspension was low. After the oral adiministration of N-556,a small amount of M2 and a trace of M3 having L-lysyl residue were detected in the portal plasma, but no hydrolytic intermediate except DSCG could be found in the general plasma. The major absorption mechanism of N-556 may thus be concluded as follows : N-556 given orally is transferred to the small intestine in essentially intact form. N-556 is then rapidly diffused to an aqueous layer on the surface of the mucosal membrane and hydrolyzed to M1. The resultant M1 is transported to the mucosal membrane and hydrolyzed to DSCG via M2. DSCG generated in the mucosal membrane is used for general circulation through the portal blood and liver. A small amount of M2 in the mucosal membrane is transported to the portal blood and hydrolyzed to DSCG in the portal blood and/or liver to make DSCG available for the general circulation.
- 公益社団法人日本薬学会の論文
- 1993-04-15
著者
-
掛谷 宣治
Research Laboratories Kyoto Pharmaceutical Industries Ltd.
-
西村 憲一
京都薬品工業株式会社
-
吉見 彰久
Research Laboratories Kyoto Pharmaceutical Industries Ltd.
-
西村 憲一
Research Laboratories, Kyoto Pharmaceutical Co., Ltd.,
-
橋詰 博之
Research Laboratories, Kyoto Pharmaceutical Industries, Ltd.,
-
北川 明子
Research Laboratories, Kyoto Pharmaceutical Industries, Ltd.,
-
北川 明子
Research Laboratories Kyoto Pharmaceutical Industries Ltd.
-
橋詰 博之
Research Laboratories Kyoto Pharmaceutical Industries Ltd.
関連論文
- Biological Activity of Drugs. XI. Relation of Structure to the Bacteriostatic Activity of Sulfonamides. (2)
- Biological Activity of Drugs. X. Relation of Structure to the Bacteriostatic Activity of Sulfonamides. (1)
- Biological Activities of Drugs. IX. Structure-Activity Relationship of Sulfonamide Carbonic Anhydrase Inhibitors.
- Biological Activities of Drugs. VIII. Structure-Activity Relationship of Sulfonamide Carbonic Anhydrase Inhibitors. (3)
- Biological Activities of Drugs. VII. Structure-Activity Relationship of Sulfonamide Carbonic Anhydrase Inhibitors. (2)
- Biological Activities of Drugs. VI. Structure-Activity Relationship of Sulfonamide Carbonic Anhydrase Inhibitors. (1)
- セファロスポリンPro-drugに関する研究 : (5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 7-[D-O-(Aminoacyl)mandelamido]-3-[[(5-methyl-1,3,4-thiadiazol-2-yl)thio]methyl]-3-cephem-4-carboxylate類の合成, 経口吸収及び抗菌活性
- N-556のラットにおける実験的抗アレルギー作用
- Studies on Prodrugs of Cephalosporins. I. Synthesis and Biological Properties of Glycyloxybenzoyloxymethyl and Glycylaminobenzoyloxymethyl Esters of 7β-[2-(2-Aminothiazol-4-yl)-(Z)-2-methoxyiminoacetamido]-3-methyl-3-cephem-4-carboxylic Acid
- Studies on the Promoting Effects of Carboxylic Acid Derivatives on the Rectal Absorption of β-Lactam Antibiotics in Rats
- KY-109,New Bifunctional Prodrug of Cephalosporin. II. : Mechanism of Oral Absorption
- Absorption Mechanism of 1,3-Bis(2-ethoxycarbonylchromon-5-yloxy)-2-((S)-lysyloxy)propane Dihydrochloride (N-556), a Prodrug for the Oral Delivery of Disodium Cromoglycate
- Pro-drugs for the Oral Delivery of Disodium Cromoglycate
- 353 Disodium cromoglycate(DSCG)プロドラッグKY-556の抗アレルギー作用
- Thromboxane A_2 Synthetase Inhibitors with Histamine H_1-Blocking Activity : Synthesis and Evaluation of a New Series of Indole Derivatives
- P-8 ジゴキシン 0.125mg 錠(ハーフジゴキシン錠 「0.125」)の同等性試験
- Indapamideの正常および高血圧発症ラットにおける降圧利尿作用